Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Jayamas Medica Industri TbkISX:OMED -0.98%91 Return-on-Tangible-Equity is 14.33% as of Mar. 2026, which is 19% below its 10-year median of 17.64. GuruFocus rates ISX:OMED with a GF Score™ of 91/100 and a GF Value™ of Rp238.29 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 758 Medical Devices & Instruments companies, PT Jayamas Medica Industri Tbk ranks better than 76.12% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. PT Jayamas Medica Industri Tbk's annualized net income for the quarter that ended in Mar. 2026 was Rp393,478 Mil. PT Jayamas Medica Industri Tbk's average shareholder tangible equity for the quarter that ended in Mar. 2026 was Rp2,746,396 Mil. Therefore, PT Jayamas Medica Industri Tbk's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 14.33%.
The historical rank and industry rank for PT Jayamas Medica Industri Tbk's Return-on-Tangible-Equity or its related term are showing as below:
ISX:OMED'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 12.33 Med: 17.64 Max: 91.46
Current: 15
During the past 7 years, PT Jayamas Medica Industri Tbk's highest Return-on-Tangible-Equity was 91.46%. The lowest was 12.33%. And the median was 17.64%.
ISX:OMED's Return-on-Tangible-Equity is ranked better than 76.12% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.055
vs ISX:OMED: 15.00
PT Jayamas Medica Industri Tbk (ISX:OMED) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
PT Jayamas Medica Industri Tbk Return-on-Tangible-Equity Related Terms
PT Jayamas Medica Industri Tbk Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk Return-on-Tangible-Equity Chart
ISX:OMED vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, PT Jayamas Medica Industri Tbk's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Jayamas Medica Industri Tbk Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PT Jayamas Medica Industri Tbk's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where PT Jayamas Medica Industri Tbk's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 14.33% mean?
PT Jayamas Medica Industri Tbk (ISX:OMED) has a Return-on-Tangible-Equity of 14.33% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PT Jayamas Medica Industri Tbk and its competitors. This is 19% below median its historical median of 17.64. Over the past decade, PT Jayamas Medica Industri Tbk's Return-on-Tangible-Equity has ranged from 12.33 to 91.46. According to the industry distribution chart, PT Jayamas Medica Industri Tbk ranks #181 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 23.9%.
Is PT Jayamas Medica Industri Tbk's Return-on-Tangible-Equity too high?
PT Jayamas Medica Industri Tbk's current Return-on-Tangible-Equity of 14.33% is 19% below median its 10-year median of 17.64. Over the past 10 years, this metric has ranged from a low of 12.33 to a high of 91.46. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.06. PT Jayamas Medica Industri Tbk's value of 14.33% is 253.4% above this industry median. Based on the distribution chart, PT Jayamas Medica Industri Tbk ranks #181 out of 758 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PT Jayamas Medica Industri Tbk ranks #181 out of 758 companies for Return-on-Tangible-Equity. This places PT Jayamas Medica Industri Tbk in the top 24% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.06. PT Jayamas Medica Industri Tbk's value of 14.33% is 253.4% above this benchmark. Historically, PT Jayamas Medica Industri Tbk's own Return-on-Tangible-Equity has ranged from 12.33 to 91.46 over the past decade. While the company's 10-year median is 17.64 vs. the industry median of 4.06, PT Jayamas Medica Industri Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.06, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Jayamas Medica Industri Tbk's current Return-on-Tangible-Equity of 14.33% is 253.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on PT Jayamas Medica Industri Tbk and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Jayamas Medica Industri Tbk's current Return-on-Tangible-Equity is 14.33%, which is 19% below median its own 10-year median of 17.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp238.29, compared to a current price of Rp202.00 — trading 15.2% below its estimated fair value. The current Return-on-Tangible-Equity is 14.33%, which is 19% below median its 10-year median of 17.64 and 253.4% above the Medical Devices & Instruments industry median of 4.06. PT Jayamas Medica Industri Tbk's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current Return-on-Tangible-Equity is 14.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be undervalued.
The current stock price of Rp202.00 is trading 15.2% below its estimated GF Value™ of Rp238.29.
GuruFocus considers PT Jayamas Medica Industri Tbk to be Modestly Undervalued.
Key valuation signals for ISX:OMED:
Return-on-Tangible-Equity: 14.33% (19% below median its 10-year median of 17.64)
GF Value™: Rp238.29 vs. price of Rp202.00 (15.2% below fair value)
Industry Position: 253.4% above the Medical Devices & Instruments median (#181 of 758)
No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Jayamas Medica Industri Tbk Business Description
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
91GF Score
Get the complete analysis for ISX:OMED
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:OMED has been successfully added to your 
